Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Placebo Eyedrops

Phase 3

JJaeb Center for Health Research

Placebo Eyedrops is one of 22 therapeutic programs targeting Myopia. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

21

Competitors

Pipeline

Status by Indication[2][1]

Indication

MyopiaRecruiting

MyopiaPhase 3

Recruiting

Competition

Competitive Landscape

58 competitors in Myopia

#DrugCompanyPhaseTrials

Atropen

FFresenius Kabi Oncology Ltd.

Alphagan

Mitosol

UUroGen Pharma Ltd.

Isopto Carpine

Oxylone

Lucentis

Mydriacyl

Lotemax

Avastin

BBio-Thera Solutions

Carboxymethylcellulose

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 3Recruiting

Myopia

NCT07095894

Clinical

Trials by Indication[1]

Myopia1 trial

A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children

Recruiting·JJaeb Center for Health Research·Phase 3·NCT07095894·348 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo Eyedrops. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo Eyedrops. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Jaeb Center for Health Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: JJaeb Center for Health Research

Related News